Clinuvel Pharmaceuticals Ltd. is an Australian-based company in the pharmaceutical industry that specializes in providing a unique product called Scenesse. Scenesse is the only approved treatment for phototoxic reactions associated with the rare genetic disease erythropoietic protoporphyria (EPP). This revolutionary treatment helps manage extreme pain and burns caused by exposure to light, ultimately improving the quality of life for patients. The patented dissolvable implant, similar in size to a rice grain, is injected underneath the skin every three months to provide continuous protection. The implant releases a synthetic drug that increases melanin production, reducing pain and enhancing light exposure tolerance for those with EPP. Clinuvel primarily generates revenue from markets in Europe and the US. With an ESG risk rating score of 22.6, Clinuvel Pharmaceuticals Ltd. has been assessed as a medium-risk company.